Netherlands-based QIAGEN N.V. (NYSE: QGEN), a $1.5b developer of molecular diagnostic equipment and assays, has acquired a 80.1% ownership stake in diagnostics instruments maker NeuMoDx Molecular, Inc. for $248m. Qiagen had purchased a 19.9% ownership stake in NeuMoDx in 2018. The acquisition builds on QIAGEN’s portfolio of automated molecular testing solutions based on PCR technology. The move also expands QIAGEN’s testing for infectious diseases including COVID-19, particularly in the U.S. market. In August, Thermo Fisher attempted an $11.5b takeover of QIAGEN that was ultimately terminated due to lack of shareholder approval. Deal terms – $248m.
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Diagnostics